1. Home
  2. ETON vs PNNT Comparison

ETON vs PNNT Comparison

Compare ETON & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$19.01

Market Cap

411.9M

Sector

Health Care

ML Signal

HOLD

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

HOLD

Current Price

$4.65

Market Cap

397.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
PNNT
Founded
2017
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
411.9M
397.7M
IPO Year
2018
2007

Fundamental Metrics

Financial Performance
Metric
ETON
PNNT
Price
$19.01
$4.65
Analyst Decision
Strong Buy
Hold
Analyst Count
3
5
Target Price
$31.00
$5.85
AVG Volume (30 Days)
285.9K
722.9K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
20.64%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,011,000.00
N/A
Revenue This Year
$107.23
N/A
Revenue Next Year
$29.72
N/A
P/E Ratio
N/A
$13.14
Revenue Growth
23.29
N/A
52 Week Low
$11.09
$4.63
52 Week High
$23.00
$7.53

Technical Indicators

Market Signals
Indicator
ETON
PNNT
Relative Strength Index (RSI) 65.46 28.30
Support Level $16.23 N/A
Resistance Level $20.01 $6.18
Average True Range (ATR) 1.11 0.15
MACD 0.12 -0.01
Stochastic Oscillator 72.64 15.83

Price Performance

Historical Comparison
ETON
PNNT

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

Share on Social Networks: